Top in allergy/asthma: Evolution of anaphylaxis management; drug allergy de-labeling

At the American College of Allergy, Asthma & Immunology Annual Scientific Meeting, Jay A. Lieberman, MD, FACAAI, discussed upcoming changes to anaphylaxis guidelines and treatment strategies, including new epinephrine delivery methods.

Emerging data suggest that intranasal and sublingual epinephrine “may be just as effective as the intramuscular route,” Lieberman told Healio. It was the top story in allergy/asthma last week.

The second top story was about how technology and patient education can be used as strategies to maintain a drug allergy de-label.

Read these and more top stories in allergy/asthma below:

VIDEO: Evolution of anaphylaxis guidelines, therapies

The future of anaphylaxis guidelines and treatments are evolving, Lieberman said. Watch video.

VIDEO: Strategies can help maintain drug allergy de-label

Utilizing technology and patient education are strategies that can maintain a drug allergy de-label, Allison C. Ramsey, MD, FACAAI, said. Watch video.

VIDEO: Natural disaster preparedness, cybersecurity essential to practice management

Allergy practices should take steps to be prepared in the event of a natural disaster or fire and to educate employees on how to mitigate cybersecurity threats, an expert said. Watch video.

Q&A: Single oral immunotherapy desensitizes children to multiple food allergens

Children with allergies to multiple foods achieved desensitization with a multi-food oral immunotherapy, data show. Read more.

Steroid, rituximab use can lead to secondary immunodeficiencies

Use of steroids and B-cell depleting therapies may lead to secondary immunodeficiencies, according to a presentation. Read more.